Spero secures $105M non-dilutive deal to fund immune-disease drug

What's the deal? Spero Therapeutics (Nasdaq: SPRO) has closed a $105 million non-recourse, non-dilutive royalty financing led by Healthcare RoyaltyDealroom has a profile for this one. Try Dealroom → (HCRx), a business of KKR. The debt is backed by a portion of future milestones and royalties from Utebzi (tebipenem pivoxil), the company's antibiotic licensed to GSK.

What's the endgame? Proceeds will primarily fund Phase 2 development of SP001, a third-generation anti-CD40L monoclonal antibody for immune-mediated diseases. Spero in-licensed the drug from Innovent Biologics under an exclusive agreement signed alongside the financing.

How it works: HCRx will collect quarterly principal and interest payments drawn solely from the GSK payments owed to Spero. Once the loan is repaid, Spero retains 35% of subsequent GSK Utebzi milestone and royalty payments.

By the numbers: The financing extends Spero's cash runway into the second half of 2029, according to updated company guidance. Shares fell roughly 7% following the announcement, trading near $2.03, against a market cap of about $126 million.

What could go wrong? Spero is assigning the majority of its future GSK Utebzi payments to service the debt, keeping just 35% after repayment. Those same milestones and royalties must cover quarterly obligations to HCRx until the loan clears.

The signal: The deal shows how cash-tight biotechs are tapping royalty-backed debt to fund pipelines without diluting shareholders — trading future upside on an approved asset for capital to advance an earlier-stage bet.

Read more: StockTitan

Image credit: Generated with Gemini